Eric has posted above an Insmed press release regarding the utility of Insulin-like Growth Factor-Binding Protein-3 (IGFBP-3)in connection with Herceptin resistant breast cancer tumors. In prior preclinical studies IGFBP-3 has also shown its utility in generally restricting tumor growth and enhancing the effect of chemotherapeutic drugs and radiation treatment.
The cross-link below will take you to Insmed's summary of preclinical studies involving IGFBP-3. You will need Adobe Reader to view the preclincial study summaries which are presented in "pdf" format. |
All times are GMT -7. The time now is 07:43 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021